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tion mediated by tubular urate transporters in physio­
logical condition 1）. Thus, hyperuricemia is caused by 
the imbalance between production and excretion of 
urate. Preeclampsia is one of the pregnancy complica­
tions which is known to be closely related to the ele­
vation of maternal urate level 2）. Although it is sug­
gested that hyperuricemia in such patients is induced 
by increased placental urate production 3）, the mecha­
nism how can urate, produced in syncytiotrophoblasts, 
enter into the plasma membrane has not been clari­
fied yet. Recently, Uehara et al. clarified that urate 
????????????
In humans, serum uric acid（urate）level is deter­
mined by the balance between hepatic production by 
the enzyme xanthine oxidase（XO）and renal excre­
Dokkyo Journal of Medical Sciences
??（1 ：31 〜 38，2017
????????
Characterization of Urate Transport System in JAR and 
JEG-3 Cells, Human Trophoblast-derived Cell Lines
Kaori Kiuchi, M.D. 1,2）, Asuka Morita, Ph.D. 1）,  
Motoshi Ouchi, M.D., Ph.D. 1）, Naoyuki Otani, M.D., Ph.D. 1）,  
Promsuk Jutabha, Ph.D. 1）, Masakatsu Nohara, Ph.D. 1）, Ichio Fukasawa, M.D., Ph.D. 2）,  
Tomoe Fujita, M.D., Ph.D. 1）, and Naohiko Anzai, M.D., Ph.D. 1,3）
1）Department of Pharmacology and Toxicology and 2）Department of Obstetrics and Gynecology,  
Dokkyo Medical University School of Medicine 
3）Department of Pharmacology, Chiba University Graduate School of Medicine
???????
Urate（uric acid）is the major inert end product of purine metabolism in humans. Since it is water solu­
ble, it requires a membranous protein called transporter for its permeation across the plasma membrane. 
Increased blood urate level is often seen in preeclampsia, but its precise mechanism remains unknown. 
Syncytiotrophoblasts function as a barrier between maternal blood and fetal one so called “blood-placental 
barrier”. So far, the expression of several urate transporters was identified in these cells, but it is still 
unclear about their contribution to urate handling in blood-placental barrier. In this study, we investigated 
the expression of urate transporters and the properties of ［14C］urate transport in both JAR and JEG-3, 
human choriocarcinoma cells as a model of human placenta. Conventional PCR analysis revealed that both 
JAR and JEG-3 cells express strongly breast cancer resistance protein（BCRP/ABCG2）mRNA. Uptake of 
［14C］urate by these cells is time-dependent with Na＋- and Cl－-independent and voltage-insensitive man­
ner and is not inhibited by benzbromarone, a representative renal urate transport inhibitor. Then, we 
focused on BCRP which shows strong mRNA expression and found that these cells have urate efflux prop­
erty that is sensitive to fumitremorgin C（FMC）, a BCRP inhibitor. These results suggest that BCRP is one 
of the important components for urate handling in human placenta in pathophysiological condition such as 
preeclampsia.
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moves through the paracellular route in placenta by 
simple diffusion using one of the human choriocarcino­
ma cell lines BeWo4）, but it is still uncertain because 
this cell is only one kind of trophoblast-derived epi­
thelial cancer cell lines and there are still other kind 
of the cells named JAR and JEG-3, normally analyzed 
together with BeWo.
In this study, we examined the expression of sever­
al urate transporters and characterized urate trans­
port properties in JAR and JEG-3 cells, other human 
choriocarcinoma cell lines that are usually used for 
the analysis of organic solute transport 5）or drug-
metabolizing enzyme 6）to further clarify the contribu­
tion of transporters for the permeation of urate in pla­
centa.
?????????????????????
Materials
［14C］Urate was purchased from Moravek Inc.（Brea, 
CA, USA）. URAT1 inhibitor benzbromarone, BCRP 
inhibitor fumitremorgin C, and other chemicals were 
purchased from Sigma-Aldrich Co.（St. Louis, MO, 
USA）. JAR（Catalog number：HTB-144TM）and JEG- 
3（Catalog number：HTB-36TM）, human choriocarci­
noma cell lines, were obtained from American Type 
Culture Collection（ATCC）（Manassas, VA, USA）.
Reverse transcription polymerase chain reaction 
（RT-PCR）
RNA samples were collected using the RNeasy Kit
（Qiagen, Venlo, Netherlands）from JAR and JEG-3 
cells. cDNA was synthesized with PrimeScriptTM RT 
reagent Kit with gDNA eraser for RT-PCR（Takara 
Bio Inc., Shiga, Japan）according to the manufacturers’ 
instructions. RT-PCR was performed as follows：ini­
tial denaturation（95℃）for 2 min, 95℃ for 30 sec, 54℃ 
for 30 sec, 72℃ for 30 sec, for 30 cycles, followed by a 
final 5 min extension at 72℃. Primers used in this 
study were shown in Table 14）. Concerning MRP4, 
primer pair 1 covers all four isoforms of MRP4 and 
primer pair 2 is specific for isoform 1（longest one）.
Transport activity of ［14C］urate
JAR cells were grown in RPMI-1640 medium（Sig­
ma-Aldrich Co., St. Louis, MO, USA）supplemented 
with 2.0 mg/L NaHCO3 and 10％ FBS and JEG-3 cells 
were grown in Minimum Essential Medium Eagle（Sig­
ma-Aldrich Co., St. Louis, MO, USA）supplemented 
with 2.2 mg/L NaHCO3 and 10％ FBS. The cells were 
seeded on poly D-lysine coated 24-well plates（1×105 
cells/well）in the fresh medium and incubated for 48 
hours at 37℃ in 5％ CO2. The medium was removed 
and the cells were washed twice with Hank’s bal­
anced salt solution（HBSS）containing 125 mM NaCl, 
4.8 mM KCl, 25 mM HEPES, 1.2 mM KH2PO4, 1.2 mM 
MgSO4, 1.3 mM CaCl2 and 5.6 mM glucose（pH 7.4）
and further incubated in the same solution at 37℃ for 
10 minutes. The uptake of 5 µM ［14C］urate in the 
cells was measured during 30 minutes incubation at 
37℃ or 4℃. Uptake was terminated by washing the 
cells three times with ice-cold HBSS7）. Then, cells 
were solubilized with 0.1N NaOH and radioactivity 
was counted by liquid scintillation spectrometry. The 
values are expressed as pmol/mg protein/min. For 
the measurement of the uptake of ［14C］urate, four to 
six wells of the cells were used for each data point. 
To confirm the reproducibility of the results, three or 
four separate experiments were performed for each 
measurement. Results from the representative experi­
ments are shown in the figures.
For urate efflux experiments, JAR and JEG-3 cells 
were pre-loaded with 5 µM ［14C］urate for 30 min­
utes at 37℃, and then the cells were washed and 
incubated with or without fumitremorgin C（1 and 5 
µM）in the bath solution for 30 minutes. The radioac­
tive both in bath solution and cells were measured to 
determine the efflux of ［14C］urate. Cells were lysed 
with 0 .1 N NaOH and radioactivity was measured 
using a liquid scintillation counter LSC-7200（Hitachi 
Aloka, Inc., Tokyo, Japan）. Protein contents of cell 
lysate were measured by Pierce BCA protein assay 
kit（Thermo Fisher Scientific, Inc., Waltham, MA, 
USA）.
Data analysis
All experiments were performed in triplicate. 
Results are presented as mean±S.E.（n＝4 to 6）. Sta­
tistical significance was analyzed by using Student’s 
t-test for two groups. p＜0.05 was considered statisti­
cally significant.
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Expression of urate transporters in JAR and JEG-3 
cells
RT-PCR was performed. As shown in Fig. 1 , 
mRNAs for OAT4, BCRP, MRP4 were expressed in 
JAR cells and mRNAs for OAT10 and BCRP were 
expressed in JEG-3 cells. Interestingly, breast cancer 
resistance protein（BCRP/ABCG2）8）mRNA was 
detected strongly in both cells.
Urate uptake by JAR and JEG-3 cells
［14C］urate uptake by JAR and JEG-3 cells were 
investigated both at 4℃ and 37℃. Urate uptake at 37
℃ were increased in a time-dependent manner, while 
urate uptake at 4℃ were hardly increased（Fig. 2A）. 
We suspected that transporters were involved in 
urate uptake of JAR and JEG-3 cells rather than dif­
f u s i on . To de te rm ine whe ther URAT 1 9）and 
URATv110）contribute to this urate uptake, we exam­
ined uptake of urate in the presence of benzbroma­
rone, which inhibits URAT1 strongly and URATv1 
weakly. JAR and JEG-3 cells were incubated with 
［14C］urate and 0, 1, 10 and 100 µM benzbromarone 
for 2 min at 37℃ or 4℃. Urate uptake didn’t change 
throughout the condition. In JEG-3 cells, urate uptake 
???????　Primers used in conventional RT-PCR
Transporters Primer sequence（5’-） Product size（bp）
URAT1
Forward AACCTCGTGTGTGACTCT
414
Reverse AAAGCAGAGGAAGAAGGG
NPT1
Forward CCAGATATCCAGGGAATC
416
Reverse AGAAGACATACGGCACAG
NPT4
Forward GCCCCAAAGAGTCTTCCTGC
505
Reverse TCCATGGATAGGAAACGG
OAT1
Forward CCGGAAGGTACTCATCTT
334
Reverse GGCCGACTCAATGAAGAA
OAT3
Forward GGAGGAGCTCAAACTCAA
419
Reverse TTGTGTAGAGGAAGAGGC
OAT4
Forward GTTCTCGAAGCTCTTGGA
445
Reverse CATGAAGATGGACTGGCT
OAT10
Forward CCCATCCCTGAAGAATGA
470
Reverse AACGTGCAGATTCTGGCA
URATv1
Forward GGCCTCAATGCAATTTGG
373
Reverse CTGCAATGATGAAGGCAG
BCRP
Forward GCAGGATAAGCCACTCAT
432
Reverse GACACTCTGTAGTATCCG
MRP4
Forward 1 TACCAGGAGGTGAAGCCCAA
555
Reverse 1 TGTCTTCCCCATGGCCATGT
Forward 2 TGGTGTGTTCGACAAAGTGC
469
Reverse 2 GTAAGGCATTCCACAGTTCC
GAPDH
Forward GCTGCTTTTAACTCTGGTAA
541
Reverse CGCGGCCATCACGCCACAGT
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with 100 µM benzbromarone was weakly inhibited at 
37℃ , indicating that neither URAT1 nor URATv1 
contributes to this uptake（Fig. 2B）. To identify the 
responsible transporters in JAR and JEG-3 cells, 
experiments with Na＋, K＋ and Cl－ substitution were 
performed. Urate uptake changed only a little in any 
conditions（Fig. 2C）. It suggested that JAR and JEG-3 
cells do not have urate transport systems similar to 
URAT1 nor URATv1.
Urate efflux of JAR and JEG-3 cells
Next, we analyzed the efflux transport of urate in 
JAR and JEG-3 cells. Urate efflux was observed in 
both JAR and JEG-3 cells（Fig. 3）. To determine 
whether an ATP-driven efflux transporter BCRP8）is 
involed in this step, urate efflux was investigated with 
or without BCRP inhibitor, fumitremorgin C（FMC）11）. 
The efflux of ［14C］urate was inhibited by FMC 
remarkably in both JAR and JEG-3 cells（Fig. 4）. Par­
ticularly, the efflux of JEG-3 cells was decreased in a 
dose-dependent manner. These results indicate that 
［14C］urate efflux via BCRP exists in both JAR and 
JEG-3 cells.
??????????
In the present study, we investigated the expres­
sion of urate transporters and the properties of urate 
transport in JAR and JEG-3, human trophoblast-
derived cancer cells. Since we found that both JAR 
and JEG-3 cells express BCRP mRNA strongly and 
urate efflux was sensitive to BCRP inhibitor FMC, 
BCRP is suggested to contribute for the permeation of 
urate produced in placental cells so called syncytiotro­
phoblasts.
Since urate is water-soluble molecule, it requires a 
membrane transport protein such as transporter for 
its permeation of plasma membrane. The identification 
of URAT1 by Enomoto et al. in 2002 9）contributed to 
advances in the accumulation of information concern­
ing molecules related to renal urate handling together 
with the identification of new molecules such as 
OAT4, URATv1, OAT10, OATv1, MRP4 and BCRP 
involved in urate transport 12,13）. In this study, we 
demonstrated by conventional PCR that JAR cell 
expresses mRNAs for BCRP as well as OAT4 and 
MRP4, and that JEG-3 cell expresses BCRP mRNA 
together with OAT10. The difference of urate trans­
port properties between JAR and JEG-3 observed in 
Figs. 2 and 3 may be due to the different expression 
profile of urate transporters.
As shown in Fig. 2 , we found that transporter-
mediated uptake of urate in both JAR and JEG-3 cells 
was based on the comparison of values at 4℃ and 37
℃. Our results are different from the one reported 
previously by Uehara et al：they reported that urate 
moves through the paracellular route by a simple dif­
fusion based on the data from one of the human cho­
riocarcinoma cell lines BeWo 4）. Since JAR and JEG-3 
????????　Expression of uric acid transporters in JAR and JEG-3 cells
RT-PCR of urate transporters was performed using collected RNA from JAR 
and JEG-3 cells. RT-PCR was performed as follows：initial denaturation（95
℃）for 2 min, 95℃ for 30 sec, 54℃ for 30 sec, 72℃ for 30 sec, for 30 cycles, fol­
lowed by a final 5 min extension at 72℃. Expression of each transporter was 
investigated by the primer pairs listed in Table 1.
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????????　Urate uptake by JAR and JEG-3 cells
?：Time courses of urate uptake were examined at 37℃（●）and 4℃（○）. 
Urate uptake of 5 µM ［14C］urate in HBSS-added JAR and JEG-3 cells was 
measured during a 30 min incubation. ?：Urate uptake was performed in the 
presence of benzbromarone. JAR and JEG-3 cells were incubated with ［14C］
urate and 0, 1, 10 and 100 µM benzbromarone for 2 min at 37℃（■）or 4℃（□）. 
?：Substitution experiments without Na＋, K＋ or Cl－ were analyzed. JAR and 
JEG-3 cells were incubated with ［14C］urate for 5 min in each HBSS. Data are 
presented as means±SE for each group. ＊ p＜0.05, ＊＊ p＜0.01.
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are used for the model of placental transport of sever­
al substances together with BeWo, it seems necessary 
to evaluate all three cells to conclude the transport 
characteristics for the model of placental transport.
Urate transport properties of JAR and JEG-3 
shown in Fig. 2 did not match to the classical urate 
transporter characteristics：they lack the dependency 
to Na＋ and Cl－ and no voltage sensitivity together 
with no benzbromarone inhibition. These characteris­
t i cs are complete ly d i f f erent f rom URAT 1 9）, 
URATv110）, OAT414）, OAT10 15） and OATv1（former­
ly NPT4）16）. Thus we did not expand our research for 
SLC（solute carrier）transporter and focused on to 
BCRP8）.
In this study, we found that urate was exported 
from the cell to the supernatant in both JAR and 
JEG-3 cells（Fig. 3）and FMC, a BCRP inhibitor, inhib­
ited urate efflux（Fig. 4）. These results indicated that 
efflux of intracellular urate seems to be related to 
BCRP. Previous report described that blood urate 
level as well as urate production enzyme xanthine 
oxidase（XO）level are increased in patients with pre­
eclampsia because of exposed oxidative stress 3）. 
Therefore, it is suggested that urate is produced in 
placental cells and accumulated urate is exported by 
ABC（ATP-binding cassttte）transporter BCRP in the 
case of preeclampsia. Although the mechanism why 
hyperuricemia occurs in preeclampsia patients is not 
clear but, to the best of our knowledge, this is the 
first report that urate transporter such as BCRP par­
ticipates urate handling in placenta.
??????????
In the present study, we investigated mRNA expre­
ssion of several urate transporters and characterized 
urate transport in JAR and JEG-3 derived from 
human trophoblast-derived cells and showed that 
BCRP, an ATP-driven efflux transporter, contributed 
the urate handling in placenta, probably for the per­
meation of urate produced in placental cells to the 
blood circulation.
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